In a study, patients with new-onset polymyalgia rheumatica (PMR) who were treated with subcutaneous tocilizumab were more likely to achieve sustained, glucocorticoid-free remission than patients who received placebo.
Search results for: hospital
New Healthcare Price Transparency Requirements Are Complicated & Vary by State
Healthcare law is ever changing, particularly with regard to price transparency. Key healthcare leaders and stakeholders have long argued for more stringent price transparency regulations in an effort to increase patient awareness regarding the cost of a hospital item or service prior to receiving the service. Such information is anticipated to enable patients to take…
Case Report: Elevated Inflammatory Markers & a Hypermetabolic Mass
Consulting rheumatologists often assess patients with atypical clinical presentations for the possibility of an underlying rheumatic disease. Inflammatory syndromes that are not clearly rheumatic in nature can be particularly challenging to diagnose. Here, we share the case of a young woman with a long-standing undiagnosed illness and highly elevated inflammatory markers, and describe the evaluation…
Vax Hesitancy? Myths & Facts for Patients
Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…
New Booklet Offers Tips for Diagnosing Lupus, Images of Presentation on Skin of Color & More Insights
For decades, rheumatologist Cindy Flower, MD, accumulated images of systemic lupus erythematosus (SLE) in her patients, as well as clinical vignettes to use in teaching at Queen Elizabeth Hospital in Bridgetown, Barbados. For decades, she has wanted to do something wide-reaching with these materials, sharing information from her practice and her mentor, the late Prof….
The 2021 ACR Awards of Distinction & Distinguished Fellows
During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…
Rheumatic Complications from Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…
The Transformative Power of Tragedy
On Sept. 11, 2001, I was at work. I had accepted a position as an assistant chief of service (ACS) for the Department of Medicine, which is Hopkins-speak for a hybrid position that involves all the administrative duties of a chief resident, plus the responsibility of an attending. For a year, I admitted patients to…
FDA Authorizes New Long-Acting, Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals
On Dec. 8, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). The product…
Therapeutics for COVID-19: An update from ACR Convergence 2021
ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 319
- Next Page »